On this page
betamethasone valerate
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 018865-001 | BETAMETHASONE VALERATE | OINTMENT | BETAMETHASONE VALERATE | Prescription | AB | RLD RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 13 | Manufacturing (CMC) | Approved | January 20, 2015 | — |
| Supplement | 11 | Labeling | Approved | December 12, 1996 | — |
| Supplement | 9 | Manufacturing (CMC) | Approved | April 29, 1996 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | March 7, 1996 | — |
| Supplement | 6 | Manufacturing (CMC) | Approved | October 24, 1988 | — |
| Supplement | 8 | Labeling | Approved | September 14, 1988 | — |
| Supplement | 5 | Manufacturing (CMC) | Approved | April 23, 1987 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | April 23, 1987 | — |
| Original application | 1 | Approved | August 31, 1983 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260319). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE: Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION: Apply a thin film of Betamethasone Valerate Cream or Ointment to the affected skin areas one to three times a day. Dosage once or twice a day is often effective. Apply a few drops of Betamethasone Valerate Lotion to the affected area and massage lightly until it disappears. Apply twice daily, in the morning and at night. Dosage may be increased in stubborn cases. Following improvement, apply once daily. For the most effective and economical use, apply nozzle very close to affected area and gently squeeze bottle.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact G&W Laboratories, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Description
openFDA Drug LabelingDESCRIPTION: Betamethasone Valerate Cream, Ointment and Lotion contain betamethasone valerate USP, a synthetic adrenocorticosteroid for dermatologic use. Betamethasone, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity. Betamethasone valerate is a white to practically white odorless crystalline powder practically insoluble in water, freely soluble in acetone and chloroform, soluble in alcohol, and slightly soluble in benzene and ether. Chemically, it is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1, 4-diene-3,20-dione 17-valerate. The structural formula is: Each gram of the 0.1% Cream contains 1.2 mg betamethasone valerate (equivalent to 1 mg betamethasone) in a soft, white, hydrophilic cream of purified water, mineral oil, white petrolatum, polyoxyl 20 cetostearyl ether, cetostearyl alcohol, monobasic sodium phosphate and phosphoric acid or sodium hydroxide (to adjust pH, if required); chlorocresol is present as a preservative. Each gram of the 0.1% Ointment contains 1.2 mg betamethasone valerate (equivalent to 1 mg betamethasone) in an ointment base of white petrolatum and mineral oil. Each gram of the 0.1% Lotion contains 1.2 mg betamethasone valerate (equivalent to 1 mg betamethasone) in a vehicle of isopropyl alcohol and water slightly thickened with carbomer 934P. Sodium hydroxide is used to adjust pH. structural formula
Overdosage
openFDA Drug LabelingOVERDOSAGE: Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).
How Supplied / Storage and Handling
openFDA Drug LabelingHow Supplied BETAMETHASONE VALERATE OINTMENT USP, 0.1% (Potency expressed as betamethasone) Rx only NET WT 15 grams Store at room temperature 15° - 30°C (59° - 86°F) [see USP Controlled Room Temperature]. E. FOUGERA & CO. A division of Fougera PHARMACEUTICALS INC. Melville, NY 11747 46289058A R06/2021 #57 Relabeled By: Preferred Pharmaceuticals Inc. NDC 68788-8496-1 15 Gram Tube NDC 68788-8496-4 45 Gram Tube
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: BETAMETHASONE VALERATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 0713-0327-15 | 0713-0327 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0327-15) / 15 g in 1 TUBE | August 27, 2015 |
| 0713-0327-37 | 0713-0327 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0327-37) / 45 g in 1 TUBE | August 27, 2015 |
| 0168-0033-15 | 0168-0033 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | 15 g in 1 TUBE (0168-0033-15) | August 31, 1983 |
| 0168-0033-46 | 0168-0033 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | 45 g in 1 TUBE (0168-0033-46) | August 31, 1983 |
| 68788-8496-1 | 68788-8496 | Preferred Pharmaceuticals Inc. | 15 g in 1 TUBE (68788-8496-1) | July 26, 2023 |
| 68788-8496-4 | 68788-8496 | Preferred Pharmaceuticals Inc. | 45 g in 1 TUBE (68788-8496-4) | July 26, 2023 |
| 71205-364-15 | 71205-364 | Proficient Rx LP | 1 TUBE in 1 CARTON (71205-364-15) / 15 g in 1 TUBE | November 20, 2019 |
| 0713-0327 | 0713-0327 | Cosette Pharmaceuticals, Inc. | — | December 19, 1985 |
| 0168-0033 | 0168-0033 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | — | August 31, 1983 |
| 68788-8496 | 68788-8496 | Preferred Pharmaceuticals Inc. | — | July 26, 2023 |
| 71205-364 | 71205-364 | Proficient Rx LP | — | December 19, 1985 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.